Evidence map›Paper›PMID 27333291›Full record

ArticlePloS one2016

Chemical Modification of Influenza CD8+ T-Cell Epitopes Enhances Their Immunogenicity Regardless of Immunodominance.

Sietske K Rosendahl Huber, Jolien J Luimstra, Josine van Beek, Rieuwert Hoppes, Ronald H J Jacobi, Marion Hendriks, Kim Kapteijn, Casper Ouwerkerk, Boris Rodenko, Huib Ovaa and 1 more

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Thioamide Analogues of MHC I Antigen Peptides.Journal of the American Chemical Society · 2023
    Article
  4. Modified influenza M1NPJ vaccines · 2023
    Article
  5. Review
  6. Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sietske K Rosendahl HuberCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Jolien J LuimstraDivision of Cell Biology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Josine van BeekCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Rieuwert HoppesDivision of Cell Biology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ronald H J JacobiCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Marion HendriksCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment, Bilthoven, the Netherlands.
Kim KapteijnDivision of Cell Biology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Casper OuwerkerkDivision of Cell Biology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Boris RodenkoDivision of Cell Biology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Huib OvaaDivision of Cell Biology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jørgen de JongeCentre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment, Bilthoven, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cells are essential players in the defense against infection. By targeting the MHC class I antigen-presenting pathway with peptide-based vaccines, antigen-specific T cells can be induced. However, low immunogenicity of peptides poses a challenge. Here, we set out to increase immunogenicity of influenza-specific CD8+ T cell epitopes. By substituting amino acids in wild type sequences with non-proteogenic amino acids, affinity for MHC can be increased, which may ultimately enhance cytotoxic CD8+ T cell responses. Since preventive vaccines against viruses should induce a broad immune response, we used this method to optimize influenza-specific epitopes of varying dominance. For this purpose, HLA-A*0201 epitopes GILGFVFTL, FMYSDFHFI and NMLSTVLGV were selected in order of decreasing MHC-affinity and dominance. For all epitopes, we designed chemically enhanced altered peptide ligands (CPLs) that exhibited greater binding affinity than their WT counterparts; even binding scores of the high affinity GILGFVFTL epitope could be improved. When HLA-A*0201 transgenic mice were vaccinated with selected CPLs, at least 2 out of 4 CPLs of each epitope showed an increase in IFN-γ responses of splenocytes. Moreover, modification of the low affinity epitope NMLSTVLGV led to an increase in the number of mice that responded. By optimizing three additional influenza epitopes specific for HLA-A*0301, we show that this strategy can be extended to other alleles. Thus, enhancing binding affinity of peptides provides a valuable tool to improve the immunogenicity and range of preventive T cell-targeted peptide vaccines.

Indexed as

Amino AcidsAmino Acid SequenceAnimalsCD8-Positive T-LymphocytesEpitopes, T-LymphocyteFlow CytometryFluorescence PolarizationHLA-A2 AntigenHLA-A3 AntigenHumansImmunodominant EpitopesInfluenza, HumanLymphocyte ActivationMice, TransgenicOrthomyxoviridae InfectionsPeptidesAmino AcidsEpitopes, T-LymphocyteHLA-A*02:01 antigenHLA-A*03:01 antigenHLA-A2 AntigenHLA-A3 AntigenImmunodominant EpitopesPeptides

Identifiers

PMID27333291
PMCPMC4917206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.